ClinicalTrials.gg
Active, not recruitingNCT05118776Updated Oct 31, 2024

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

A Phase 3 interventional study of ASC40 tablets and Placebo tablets in Recurrent Glioblastoma, sponsored by Ascletis Pharmaceuticals Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Ascletis Pharmaceuticals Co., Ltd. (part of Ascletis Pharma Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Glioblastoma with a site in China — 73 open to participants now, 80 under way, 7 of them phase 3. Glioblastoma · China.

Enrollment
18th of 127
136 · median 36
Started
2022
with 17 others
Phase 3
11 of 142
3 open now
Primary completion
2025-06
later than 15 of 79 live
Registered
57th of 142
by date

Among the 142 studies in Glioblastoma with a site in China, this one is the 18th largest by enrollment of the 127 interventional ones that give a count, is one of 18 that started in 2022, is one of 11 in phase 3, reaches primary completion later than 15 of the 79 other live ones, and was the 57th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

73 of the 142 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.

03

Conditions studied

  • Recurrent Glioblastoma

Browse trials for

Keywords

  • ASC40
  • Recurrent Glioblastoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Age ≥18 years old, both male and female;
    1. confirmed glioblastoma;
    1. Patients with glioblastoma who have failed standard treatment (surgery, Stupp regimen), were diagnosed by MRI and evaluated by RANO standard to support the first recurrence. Stupp regimen needs to complete at least 6 medication cycles.

Exclusion criteria

Exclusion Criteria:

    1. Use low molecular weight heparin and warfarin within 35 days before randomization;
    1. Arterial or venous thrombosis (such as cerebral infarction, myocardial infarction, venous thrombosis of lower limbs, arterial embolism of lower limbs, pulmonary embolism, etc.) occurred within 6 months before randomization
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    ASC40

    ASC40 tablets 100mg/m\^2 and bevacizumab 10mg/kg.

    Drug: ASC40 tablets · Drug: Bevacizumab

  • Placebo comparator
    Placebo

    Placebo and bevacizumab 10mg/kg.

    Drug: Placebo tablets · Drug: Bevacizumab

Interventions

  • ASC40 tablets administered orally once daily

    Also known as: TVB-2640

  • DrugPlacebo tablets

    Placebo administered orally once daily.

  • Bevacizumab once every 2 weeks, intravenous drip.

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    The time of progression or death from any cause in randomly grouped diseases (whichever comes first) was compared with the control group (evaluated by Independent Imaging Evaluation Committee \[IRC\])

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months

  2. Total survival

    the time from random grouping to death, compared with the control group.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months

Secondary outcomes

  1. Objective remission rate

    It is evaluated once in the 4th week after using experimental drugs (experimental drug group or control group), and then every 8 weeks until the disease progresses or dies (evaluated by \[IRC\]).

    Time frame: Week 4 to Month 6 (every 8 weeks)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jun 2025, 41 months after the start.

Of 44 phase 3 interventional studies under Glioblastoma, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 87. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Nov 12, 2021
StartActual
Jan 21, 2022
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05118776
Responsible party
Sponsor
First posted
Nov 12, 2021
Start date
Jan 21, 2022
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Oct 31, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion